The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany.

Health Econ Rev · 2020 · PMC7071579 · PMID 32172494

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Since there is an increasing trend for combination therapies in oncology, the number of additive study designs will rise in future and the results of the analysis can be validated with higher numbers of cases for the different study design categories.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.